Physician profile
Yi Pang
NPI 1386637791
$11,141.15
in general payments reported to CMS, 2019-2025
7 companies · $71.65 in 2025
The $71.65 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,000 · 2022: $4,000 · 2023: $2,858 · 2024: $211 · 2025: $71.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,500 · Food and Beverage: $502 · Consulting Fee: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,500.00 |
| Food and Beverage | $502.45 |
| Consulting Fee | $138.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $10,610.26 | 2021-2023 | Misight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $225.95 | 2024-2025 | Xdemvy |
| Topcon Healthcare, INC. | $222.12 | 2023-2025 | |
| Abbvie INC. | $34.33 | 2023 | |
| Bausch & Lomb Americas INC. | $25.36 | 2024 | Xiidra, Miebo |
| Alcon Vision LLC | $23.13 | 2024 | Total30 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Pang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.